JERUSALEM, Feb. 21 /PRNewswire/ -- Oramed Pharmaceuticals Inc. further enhances its Scientific board of directors with the addition of Prof. Ele Ferrannini. Having published over 350 original papers and 50 book chapters he is amongst the “highly cited scientists.” (ISIhighlycited.com). One of many great honors achieved for Prof. Ferrannini includes being elected a past President to the EASD, European Association for the Study of Diabetes. The Association is based on individual membership and embraces scientists, physicians, laboratory workers, nurses and students from all over the world who are interested in diabetes and related subjects for Europe, such that the ADA, American Diabetes Association does in America.
Prof. Ferrannini has worked with various institutions including the Department of Internal Medicine, University of Pisa School of Medicine, and CNR (National Research Council) Institute of Clinical Physiology, Pisa, Italy; Diabetes Division, Department of Medicine, University of Texas Health Science Center at San Antonio, Texas, USA. He has also had extensive training focused on microbiology, immunology, endocrinology, and specializing in diabetes studies. Prof. Ferrannini has received a Certificate of the Educational Council for Foreign Medical Graduates from the University of Bologna, and with cum laude honors completed a subspecialty in Diabetes and Metabolic Diseases from the University of Torino.
CEO, Nadav Kidron stated, “We are very pleased with this new addition to the Oramed family, because he brings not only a strong mind, but accolades from the commercial pharmaceutical world, as well as his many other honorable accomplishments in the diabetes realm.” Oramed Pharmaceuticals looks forward to what Prof. Ferrannini can bring to the table with the myriad of international diabetes council memberships, strong resume, and accolades in medicine.
About Oramed Pharmaceuticals, Inc:
Oramed Pharmaceuticals’ is an Israeli based company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimen. Oramed is currently developing an orally soft gel insulin capsule for the treatment of diabetes. The Company is also pursuing the development of oral delivery solutions for other drugs and vaccines.
For more information on Oramed Pharmaceuticals please visit our website: www.oramedpharma.com
Investor Relations Contact: Oramed Pharmaceuticals, Inc. Vinisha Agnihotri (646) 467-2252 info@oramedpharma.comwww.oramedpharma.com
Oramed Pharmaceuticals Inc.
CONTACT: Vinisha Agnihotri of Oramed Pharmaceuticals, Inc.,+1-646-467-2252, info@oramedpharma.com
Web site: http://www.oramedpharma.com/
